3 citations
,
July 2025 in “Obesity Facts” This review examines how GLP-1 receptor agonists might impact metabolic and reproductive outcomes in polycystic ovary syndrome, but it reports no new clinical findings and highlights the need for further research.
This article discusses the challenges in diagnosing and treating polycystic ovary syndrome in adolescents, emphasizing the importance of lifestyle changes and a systematic therapeutic approach but reports no new clinical findings.
August 2026 in “International Journal of Science and Research (IJSR)” This review summarizes the mechanisms, applications, and considerations of therapeutic peptides in aesthetic, metabolic, and endocrine medicine, highlighting their promise despite some limitations in bioavailability and long-term safety data.
1 citations
,
September 2025 in “Dermatology and Therapy” This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.
September 2025 in “Cureus” This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.